Becton, Dickinson & Co: stocks, financial statements

Dividends News

Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates through two worldwide business segments: BD Medical and BD Life Sciences. The BD Medical segment produces medical devices that are used in healthcare settings. This segment product includes needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Life Sciences segment produces products for the safe collection and transport of diagnostic specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal products and services in the Life Sciences segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; plated media; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunology and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

  • BDX Ticker
  • NYSE Exchange
  • 76,032 Employees
8 rated
Disable ads for free

Financial statements — Becton, Dickinson & Co

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
17B 17B 16B 12B 12B
Cost Of Revenue
9.5B 9B 8.7B 6.2B 6.5B
Gross Profit
7.6B 8.3B 7.3B 5.9B 6B
Research and Development
1.1B 1.1B 1B 770M 830M
Selling General and Admin
4.3B 4.3B 4B 2.9B 3B
Operating Expense
15B 15B 14B 9.9B 10B
Operating Income
1.8B 2.2B 2.2B 2.2B 2.2B
Other Income Expense Net
0 0 0 0 0
1.8B 2.2B 2.2B 2.2B 2.2B
Interest Income
520M 630M 640M 450M 370M
Pretax Income
990M 1.2B 1.2B 980M 1.1B
Income Tax
110M -57M 860M -120M 97M
Minority Interest
0 0 0 0 0
Net Income
770M 1.1B 160M 1B 980M
Net Income Basic
770M 1.1B 160M 1B 980M
20 ← 16 2020 2019 2018 2017 2016
Current cash
2.8B 570M 1.2B 14B 1.6B
Short term investments
890M 1.1B 1.3B 870M 820M
2.4B 2.3B 2.3B 1.7B 1.6B
2.7B 2.6B 2.5B 1.8B 1.7B
Other current assets
890M 1.1B 1.3B 870M 820M
Current assets
9B 6.7B 7.4B 19B 6.4B
Long term investments
45B 45B 46B 19B 19B
Property plant equipment
5.9B 5.7B 5.4B 4.6B 3.9B
24B 23B 24B 7.6B 7.4B
Intangible assets
14B 15B 16B 5.9B 6.4B
Other assets
1.7B 1.1B 1.1B 1B 1.5B
Total assets
54B 52B 54B 38B 26B
Accounts payable
1.4B 1.1B 1.1B 800M 670M
Current long term debt
710M 1.3B 2.6B 200M 1B
Other current liabilities
3.8B 3.3B 3.5B 2.3B 2.7B
Total current liabilities
5.8B 5.7B 7.2B 3.3B 4.4B
Long term debt
17B 18B 19B 19B 11B
Other liabilities
7.2B 6.9B 6.8B 2.8B 3B
Minority Interest
0 0 0 0 0
Total Liabilities
30B 31B 33B 25B 18B
Common stock
280M 270M 260M 220M 210M
Retained earning
13B 13B 13B 13B 13B
Treasury stock
-6.1B -6.2B -6.2B -8.4B -8.2B
Capital surplus
Shareholder equity
24B 21B 21B 13B 7.6B
Net tangible assets
-14B -17B -19B -510M -6.1B
20 ← 16 2020 2019 2018 2017 2016
Net Income
770M 1.1B 160M 1B 980M
2.2B 2.3B 2B 1.1B 1.1B
Changes in receivables
53M 26M 580M 130M 0
Changes in inventories
160M 130M 630M 99M -240M
Cash change
2.3B -590M -13B 13B 120M
Cash flow
3.5B 3.3B 2.9B 2.6B 2.6B
Capital expenditures
-810M -960M -900M -730M -690M
Investing activity other
Total investing cash flows
-1.2B -740M -16B -880M -670M
Dividends paid
Net borrowings
14B 18B 19B 3.8B 9.2B
Other financing cash flows
Cash flow financing
22M -3.2B -58M 11B -1.8B
Exchange rate effect